Similarly, the VisuDep-F Frozen
Factor IX Deficient Plasma is developed for use as a substrate plasma in the quantitative detection of
Factor IX activity in citrated plasmas utilising a clot-based assay.
These assays include VisuLize Factor VIII Antigen ELISA Kit, VisuLize
Factor IX Antigen ELISA Kit, VisuLize Factor XI Antigen ELISA Kit and VisuLize TAFI Antigen ELISA Kit.
The programme is aimed at prevention and treatment of bleeding events in patients with
factor IX deficiency.
AMT said that it is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a
factor IX gene therapy produced using its proprietary AAV production system.
AMT is reportedly preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a
factor IX gene therapy produced using its proprietary AAV production system.
IB1001 is an intravenous recombinant
factor IX (rFIX) intended for the treatment and prevention of bleeding in individuals with haemophilia B.
12 January 2012 - CSL Behring, a plasma protein therapeutics firm owned by Australian CSL Ltd (ASX:CSL), said today it had kicked off its global Phase II/III multi-centre study designed to assess the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation
factor IX with recombinant albumin (rIX-FP).
M2 EQUITYBITES-February 3, 2011-Inspiration Biopharmaceuticals reports non-Inferiority of IB1001, Its recombinant
factor IX for Haemophilia B(C)2011 M2 COMMUNICATIONS http://www.m2.com